Retinal microvascular features are associated with CMR measures of subclinical
cardiovascular dysfunction

Cian Wade[1], Alicja R Rudnicka[2], Hana El Diwany[3], Charlotte Zheng[3], Ian Yeung[3], Robin D
Hamilton[3], Masliza Mahmod[4,5], Helena B Thomaides Brears[5], Charlie Diamond[5], Ravi
Pattanshetty[5], John Anderson[6], Ryan Chambers[6], Roshan A Welikala[7], Jiri Fajtl[7], Sarah A
Barman[7], Elijah R Behr[1], Christopher G Owen[2]

Corresponding author:

Dr Cian Wade MD, MA, MPH, MRCP
cwade@citystgeorges.ac.uk

Cardiovascular and Genomics Research Institute,
City St George's, University of London,
Cranmer Terrace,
London,
SW17 0RE

[1]Cardiovascular and Genomics Research Institute, City St George's, University of London,
London, UK; [2]Population Health Research Institute, City St George's, University of London,
London, UK; [3]Moorfields Eye Hospital NHS Foundation Trust, London, UK; [4]Division of
Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford,
UK; [5]Perspectum Ltd., Oxford, UK; [6]Homerton Healthcare NHS Foundation Trust, London,
UK; [7]Kingston University, London, UK

Abstract

Aims

Microvascular dysfunction is implicated in the pathogenesis of many cardiovascular (CV) diseases, with retinal imaging providing a non-invasive window into microvascular health. Prior evidence links retinal microvascular features (RVF) with cardiac structure and function, yet these relationships remain incompletely characterised. This study systematically examined associations between RVFs and measures of subclinical CV dysfunction derived from CMR imaging.

Methods and results

182 participants with type 2 diabetes were considered for inclusion in this cross-sectional study. Fifteen CMR measures of cardiac structure, function, tissue characterisation, adiposity, and aortic distensibility were derived. 128 participants (70%) had eligible retinal images. An artificial intelligence (AI)-enabled retinal image analysis tool (QUARTZ) quantified eight RVFs: arteriolar and venular diameter, area, calibre uniformity, and tortuosity. Multivariable regression examined RVF-CMR associations, expressed as change in CMR measures per 1-standard deviation (SD) increase in RVF. Five RVF-CMR associations remained significant after adjustment for confounders. Venular tortuosity was associated with a 0.5ms greater left ventricular (LV) T2 mean, 0.6% worsening in LV global longitudinal strain, and a 2 mL greater left atrial max volume. Arteriolar calibre uniformity and venular area were each associated with 9ms lower LV T1 mean and 0.2×10^{-3} mmHg^{-1} greater proximal descending aortic distensibility, respectively.

Conclusion

In a diabetic cohort, we identified novel and biologically coherent associations between RVF and CMR measures. Notably, venular tortuosity was associated with a constellation of CMR

46   changes consistent with subclinical myocardial dysfunction. These findings support the

47   potential role of retinal imaging in evaluating CV dysfunction prior to overt disease.

Introduction

Features of the retinal microvasculature are predictive of a range of cardiovascular (CV) diseases[1,2]. Numerous prospective studies have demonstrated an association between narrower retinal arteriolar diameters and coronary heart disease, hypertension, and heart failure[2,3], while wider retinal venular diameter is associated with incident stroke[4].

Beyond associations with clinically apparent, or overt, CV disease, evidence is emerging of the relationship between retinal microvascular features (RVFs) and indicators of subclinical CV dysfunction. Changes in arteriolar geometric features, including vessel branching angles and tortuosity are related to echocardiographic features of maladaptive cardiac remodelling[5]. Early features of macrovascular disease such as arterial and aortic stiffness are associated with narrower retinal arteriolar diameter[6,7]. Cardiovascular magnetic resonance (CMR) imaging is the gold-standard technique for characterisation of many subclinical CV abnormalities. A recent study examining RVFs against a limited set of CMR phenotypes found a significant correlation between central retinal venular equivalent and LV mass/volume ratio[8]. Notably however, when employing end-to-end deep-learning models, they found that retinal images had poor predictive performance for classifying binary outcomes of CMR-derived subclinical CV disease. This points to a clear evidence gap regarding the relationship between more granular measures of the retinal microvasculature and comprehensive CMR phenotypes.

CMR is not a point of care test and patients with subclinical disease will not routinely be referred for CMR, limiting its utility for diagnosing and monitoring early CV disease. The comparative accessibility and low-cost of retinal imaging has heightened interest in its utility as a non-invasive and scalable method of screening for CV disease. The case for using retinal imaging in this way rests on the retinal microvasculature providing a window into systemic

vascular health[9]. Microvascular dysfunction is a hallmark of many CV diseases, frequently

preceding and occurring in parallel to macrovascular disease due to both vascular beds'

shared susceptibility to systemic biochemical and haemodynamic factors[10,11,12].

In this cross-sectional study, we systematically examined associations between features of the

retinal microvasculature and CMR measures of subclinical CV dysfunction in a cohort of

adults with type 2 diabetes. A key methodological advance of this study, compared to prior

work, is the use of a fully-automated artificial intelligence (AI)-enabled system to quantify

granular retinal microvascular features derived from the whole retinal image and examine

these outputs against comprehensive CMR phenotypes.

Methods

Study design

The UK Imaging Diabetes Study (UKIDS, clinical trial registration number: NCT05057403) is an ongoing real-world, multi-centre prospective cohort study with clinical outcome collection of individuals with type 2 diabetes and without a recent history of incident CV disease. UKIDS participants recruited from Moorfields Eye Hospital NHS Foundation Trust in London, UK, between June 2022 – September 2025 were considered for inclusion. All participants had type 2 diabetes and were having regular outpatient retinal monitoring as part of their routine diabetic management. Exclusion criteria were evidence of incident CV event(s) within 12 months prior to consent, including myocardial infarction, unstable angina, heart surgery, ischaemic stroke, and transient ischaemic attack. Other exclusion criteria included known liver disease, known significant renal tract abnormalities, alcohol dependency, and contraindication to MR scanning.

CMR data collection & processing

All participants underwent a standardised multi-organ multiparametric MR scan (CoverScan™; Perspectum, Oxford) on a 3T scanner at the Alliance Medical Imaging Centre, London, UK[13]. Acquired CMR images were processed by trained radiographers and MR technologists blinded to clinical data. Comprehensive CMR measures were derived, including: left ventricle ejection fraction (LVEF); LV end diastolic volume indexed to body surface area (BSA) (LVEDVi); LV end systolic volume BSA (LVESVi); LV stroke volume BSA (LVSVi), LA max volume BSA (LAVi) LV mass BSA (LVMi), LV wall thickness (LVWT), LV T1 and T2 mean relaxation times averaged across all 16 American Heart Association (AHA) myocardial segments derived from the three short-axis views excluding the apex, LV global longitudinal strain (LV GLS), LV global circumferential strain (LV

GCS), LV global radial strain (LV GRS), epicardial adipose tissue (EAT), pericardial adipose

tissue (PAT), and aortic distensibility measures (supplementary table 1). Data were centrally

curated and quality-controlled. A cardiologist accredited to European Association of

Cardiovascular Imaging level 3 for CMR independently reviewed all cardiac scans. Where

pathology was identified, consensus was sought from a second independent cardiologist with

this same accreditation. Scans were reviewed to exclude regional wall motion abnormalities,

clinically significant valvular abnormalities, and other cardiac pathology. If a given CMR

measure had a reporting completion of <70% across included participants, then this measure

was not included in the analysis. Demographic and self-reported clinical information were

collected from participants by UKIDS researchers during a face-to-face consultation prior to

CMR images acquisition (supplementary table 2).

Retinal image collection & processing

Macular centred retinal images of participants were searched for on imaging databases held at

Moorfields Eye Hospital NHS Foundation Trust and the North East London Diabetic Eye

Screening programme with the following selection criteria applied: colour fundus image of

either eye captured with a $45^{\square}$ field of view; retinal image captured within a 2-year period

either before or after the date the CMR images were acquired; quality of retinal image ≥70%

(as per QUARTZ methodology outlined below). Where multiple retinal images met the

inclusion criteria, the single image with the highest quality was selected.

A fully-automated artificial intelligence (AI)-enabled system (QUARTZ)[14] was applied to

extract and quantify thousands of measures related to the retinal microvasculature within each

single retinal image. QUARTZ uses deep learning to classify retinal vessels as an arteriole or

venule, map the optic disc, and calculate an image quality score ranging from 0-100%. For

this study, eight RVF measures were used from QUARTZ's output: arteriolar and venular

diameter (µm), area (mm^2), calibre uniformity (1/µm), and tortuosity (arbitrary units). We

define vessel calibre uniformity as the variability of the diameter of vessels within an

individual's retina. This is calculated by the median standard deviation of vessel diameter

along vessel segments, computed per image and inverted to normalise. Therefore, greater

vessel calibre uniformity indicates lower variability of diameter, and vice-versa. Pixels from

each retinal image were converted to physical units (in microns) using the QUARTZ output

of the optic disc vertical diameter as a calibration reference standard[15]. RVF diameter, calibre

uniformity, and tortuosity were calculated for each identified vessel and an average (weighted

by length of the vessel segment) calculated for each participant's image. The RVF area

measure represents the total arteriolar or venular area in each image.

Statistics

Statistical analysis was carried out using Stata (StataCorp LLC. Stata Statistical Software:

Release 19.5. College Station (TX); 2024). See supplementary table 3 for additional details

on statistical methods. Participant demographic and clinical characteristics were reported, as

well as RVF and CMR measure mean and standard deviation (where normally distributed) or

median and interquartile range (where non-normally distributed). A participant was excluded

from further analysis if any RVF or CMR measure had a |z| score >4, to minimise the

influence of potentially artefactual retinal vessel or CMR measurements.

Pearson's correlation was performed on all 8 RVFs paired with all CMR measures that met

≥70% reporting completion, excluding unindexed volumetric measures, yielding 120 RVF-

CMR pairs. For each of the RVF-CMR pairs, participants with missing data for the CMR

measure were excluded from that correlation analysis. To address multiple testing, we applied

a multi-step selection strategy to shortlist RVF-CMR pairs for further regression analysis.

First, we required associations to demonstrate both a minimum effect size ($|r| \geq 0.15$) and

statistical significance ($p<0.05$). Second, we evaluated the biological feasibility of

relationships meeting this threshold.

Where normality violations were identified, log transformation was attempted and robust

standard errors applied where violations persisted. Systolic blood pressure (SBP) was

unrecorded among 16 (12.5%) participants. Following a Missing at Random (MAR)

assessment, multiple imputation by chained equations with predictive mean matching was

used to handle missing SBP data.

Multivariable linear regression was performed on multiply imputed datasets to predict CMR

measures from RVF. Where a CMR measure was missing for the measure under analysis,

participants were dropped without imputation. Sequential models 1-6 adjusted for age, sex,

SBP, diabetes duration, and time between retinal and CMR image acquisition as potential

confounders. Model 6 additionally incorporated a centre-specific fixed effect ($\alpha\Box$) to account

for potential variation in retinal image acquisition between sites (supplementary table 4).

Regression coefficients are reported as unstandardized (β represents change in CMR measure

units per 1-standard deviation [SD] increase in RVF) and standardized (βSD represents

change in SD units of CMR measure per 1-SD increase in RVF), with 95% confidence

intervals and significance set at $\alpha=0.05$. Sensitivity analysis assessed stability of β estimates

to a ~10% reduction in sample size (supplementary table 3e).

Ethics

Informed written consent was obtained from all study participants enrolling in the UKIDS

trial. Ethical approval for UKIDS was provided by the West Midlands – Solihull research

ethics committee (ethics reference 20/WM/0007). Retinal imaging data used from the North

East London Diabetic Eye Screening programme was approved by NHS Health Research

Authority and Health and Care Research Wales (Integrated Research Application System

number 265637). This study was conducted in accordance with the Declaration of Helsinki.

Results

Demographic & clinical characteristics

182 participants in the UKIDS study recruited from Moorfields Eye Hospital NHS
Foundation Trust underwent CMR imaging between June 2022 and September 2025. 129
(71%) of these had retinal images which met the inclusion criteria. One participant (0.8%)
was excluded due to extreme RVF measurements (venular diameter Z=4.2, arteriolar area
Z=7.8, venular area Z=8.4), indicating likely imaging artefact. Therefore, 128 participants
(70%) were included for analysis (Figure 1). No systematic demographic, RVF or CMR
differences were observed between the 128 included and 54 excluded participants. Of the
included participants, 88 (69%) were male, 40 (31%) were female and their mean age was 62
years (SD 9) (Table 1). 37% were of White ethnic origin, 32% South Asian, 23% Black, and
8% from other groups. Mean duration of type 2 diabetes was 17 years (SD 9), with mean SBP
of 138mmHg (SD 17), diastolic blood pressure of 79mmHg (SD 9), and mean BMI of 29
kg/m² (SD 5). 8% were current smokers, 22% past smokers, and 70% had never smoked.
68% of patients had a known diagnosis of hypertension. Previous CV events were rare (5%
myocardial infarction, 5% stroke, 2% angina, 0% heart failure), with all events occurring >12
months prior to recruitment.

205 **Figure 1: Participant flow diagram**

208 **Table 1: Baseline characteristics of included participants**

209 Mean (SD) unless otherwise stated

Demographic characteristics	Value
Participants included (n)	128
Age[1] (years)	62 (9)
Sex (n, % male)	88 (69%)
Ethnicity (%, n participants)	
White	37% (47)
South Asian	32% (40)
Black	23% (29)
Other	8% (10)
Clinical characteristics	
Duration of type 2 diabetes[1] years	17 (9)
Days between CMR and retinal image	179 (192)
Systolic blood pressure mmHg	138 (17)
Diastolic blood pressure mmHg	79 (9)
BMI (kg/m²)	29 (5)
Current smoker	8% (10)
Past smoker	22% (28)
Never smoker	70% (70%)
CV disease history (%, n participants)	
Hypertension	68% (87)
Myocardial infarction	5% (7)
Stroke	5% (7)
Angina	2% (3)
Heart failure	0% (0)
Retinal vessel feature	
Arteriolar diameter (μm)	77.3 (11.9)
Venular diameter (μm)	81.4 (13.6)
Arteriolar area (mm^2)	4.2 (1.3)
Venular area (mm^2)	4.6 (1.7)
Arteriolar calibre uniformity (1/μm)	0.1 (0.03)
Venular calibre uniformity (1/μm)	0.1 (0.03)
Arteriolar tortuosity (arbitrary units)	1.2 (0.4)
Venular tortuosity (arbitrary units)	1.4 (0.3)
CMR measure	
LV ejection fraction (%)	58 (6)
LV end diastolic volume BSA (mL/m^2)	70 (14)
LV end systolic volume BSA (mL/m^2)	30 (8)
LV stroke volume BSA (mL/m^2)	40 (8)
LA max volume BSA (mL/m^2)	27 (10)
LV mass BSA (g/m^2) (Median, IQR)	49 [43 – 55]
LV wall thickness (mm)	12 (2)
LV T1 mean (ms)	1213 (35)
LV T2 mean (ms)	39 (2)
LV global longitudinal strain (%) (Median, IQR)	-16 [-18 , -15]
LV global circumferential strain (%)	-17 (3)
LV global radial strain (%) (Median, IQR)	28 [24 – 31]
Epicardial adipose tissue (cm^2)	11 (3)
Pericardial adipose tissue (cm^2)	26 (13)
Proximal descending aortic distensibility (x10^{-3}mmHg^{-1}) (Median, IQR)	1.5 [1.0 – 2.1]

210 IQR: Interquartile range; BMI: Body mass index; BSA: Body surface area; [1]Referenced to date of CMR; Ethnicity % relates to the 126
211 participants where ethnicity was recorded; BP was recorded in 112, BMI in 125, all other measures recorded in all 128 participants

CMR and RVF baseline characteristics

Fifteen CMR measures met the threshold of ≥70% reporting completeness and were included for further analysis (table 1; CMR measure reference values are in supplementary table 5). LV function and volumes were consistent with preserved systolic function (LVEF 58%, LVESVi 30 mL/m^2, and LVSVi 40mL/m^2). Normal LVEDVi (70mL/m^2), LVMi (49g/m^2), LAVi (27mL/m^2) and high-normal LVWT (12mm) indicated there was no evidence of adverse chamber remodelling.

Mean LV T1 (1213ms) and T2 (39ms) signals were within a normal range. LV GLS (-16%) and LV GCS (-17%) were mildly impaired, while LV GRS (median 28%) was normal. Mean EAT (11cm^2) and PAT area (26cm^2) were normal. Mean proximal descending aortic distensibility (PDAoD) was reduced (1.5 x10^{-3}mmHg^{-1}), consistent with increased arterial stiffness observed in diabetes[16].

Participant RVF measures derived from QUARTZ are presented in table 1. Arteriolar diameter (77.3μm) and area (4.2mm^2) were smaller than venular diameter (81.4μm) and area (4.6mm^2). Arteriolar calibre uniformity and venular calibre uniformity (0.1 1/μm) were comparable. Tortuosity was lower among arterioles (1.2) than venules (1.4).

Correlation analysis

Correlation analysis was performed for the 120 included RVF-CMR pairs (supplementary

table 6). Overall, 15 of these pairs reached the threshold of |r| ≥0.15 and p<0.05 for inclusion

in multivariable regression analysis. Correlations not reaching this threshold included those

between RVF measures and LVEF, LVEDVi, LVESVi, LVSVi, LVMi, LVWT, and LV GCS

and LV GRS. While the correlation between venular tortuosity and PAT area met threshold

for inclusion, the negative directionality was considered to lack biological plausibility and

was therefore excluded from subsequent analysis. A further two pairs were selected for

regression due to borderline statistical significance and biological plausibility of a potential

relationship (venular area and LV GRS, r=0.18, p=0.052; and venular area and LVEF,

r=0.15, p=0.097). This resulted in a final selection of 16 RVF-CMR pairs for further analysis

with multivariable regression (table 2).

Model diagnostics and missing data

Residuals from three RVF-CMR pairs involving PDAoD showed marginal normality

violations, with robust standard errors applied for these regressions. The MAR assumption

was well supported with no systematic differences between participants with and without

recorded SBP (supplementary tables 7-8).

Multivariable regression

Five of the 16 RVF-CMR pairs revealed statistically significant associations in fully adjusted

multivariable linear regression models (table 2). Venular tortuosity was the RVF most

consistently associated with CMR measures. Each 1-SD increase in venular tortuosity was

associated with a 1.9mL (95% confidence interval, 0.1 - 3.8mL) increase in LAVi, 0.6% (0.2

- 1.1%) worsening of LV GLS, and 0.5ms (0.1 - 0.8ms) increase in LV T2 mean. Each 1-SD

increase in venular area was associated with a 0.2 x10^{-3}mmHg^{-1} (0.02 - 0.4 x10^{-3}mmHg^{-1})

increase in PDAoD. Arteriolar calibre uniformity was the only non-venular RVF measure

that had a statistically significant association with a CMR measure. Each 1-SD increase in

arteriolar calibre uniformity was associated with an 8.8ms (-17.4 , - 0.2ms) decrease in LV

T1 mean. No significant associations were found in regressions involving LVEF (with

venular area, p=0.102) and EAT (with arteriolar tortuosity, p=0.331). Arteriolar diameter,

venular calibre uniformity and arteriolar tortuosity were RVF predictors not found to be

significantly associated with any of the outcome CMR variables. Changes in SD units of

CMR measure per 1-SD increase in RVF (βSD) indicated a moderate magnitude of effect for

the five significant associations (figure 2).

Relatively modest median changes in the β regression coefficient estimates and no change in

directionality of associations were observed across sequential models (supplementary table

9). Sensitivity analysis assessing coefficient stability under reduced sample size showed

generally low coefficients of variation (median 19%), suggesting the primary significant

associations identified through multivariable regression were robust (supplementary table

10).

Table 2: Correlation & fully adjusted regression models for the 16 RVF-CMR associations

Predictor RVF variable	Outcome CMR variable	Correlation		Fully adjusted regression			
		r	p-value	β	$β_{SD}$	p-value	n
Arteriolar diameter	LV T1 mean (ms)	0.19	0.041	5.6 (-0.91 - 12.17)	0.16	0.091	120
Arteriolar diameter	LV T2 mean (ms)	0.20	0.027	0.3 (-0.13 - 0.64)	0.11	0.197	123
Arteriolar area	PDAoD (x10⁻³mmHg¹)	0.28	0.008	0.2 (-0.01 - 0.36)	0.18	0.057	89
Venular area	LV Ejection Fraction	0.15	0.097	0.9 (-0.18 - 1.96)	0.15	0.102	121
Venular area	LV Global Radial Strain (%)	0.18	0.052	1.1 (-0.03 - 2.29)	0.17	0.056	114
Venular area	PDAoD (x10⁻³mmHg⁻¹)	0.25	0.017	0.2 (0.02 - 0.38)*	0.19*	0.032	89
Arteriolar CU	LV T1 mean (ms)	-0.25	0.006	-8.8 (-17.35 , -0.21)*	-0.25*	0.045	120
Arteriolar CU	LV T2 mean (ms)	-0.25	0.006	-0.1 (-0.62 - 0.43)	-0.04	0.717	123
Venular CU	LV T1 mean (ms)	-0.21	0.021	-6.2 (-14.95 - 2.51)	-0.18	0.161	120
Venular CU	LV T2 mean (ms)	-0.28	0.002	-0.1 (-0.67 - 0.39)	-0.06	0.594	123
Venular CU	PDAoD (x10⁻³mmHg⁻¹)	0.24	0.027	0.1 (-0.15 - 0.33)	0.09	0.462	89
Arteriolar tortuosity	Epicardial adipose tissue (cm²)	0.19	0.046	0.3 (-0.33 - 0.97)	0.10	0.331	115
Venular tortuosity	Left atrial volume (ml/m²)	0.21	0.02	1.9 (0.07 - 3.78)*	0.20*	0.042	121
Venular tortuosity	LV T1 mean (ms)	0.19	0.042	5.9 (-0.19 - 12.02)	0.17	0.058	120
Venular tortuosity	LV T2 mean (ms)	0.25	0.005	0.5 (0.10 - 0.82)*	0.20*	0.013	123
Venular tortuosity	LV Global Longitudinal Strain (%)	0.19	0.047	0.6 (0.19 - 1.08)**	0.26**	0.006	114

CU: Calibre uniformity; PDAoD: proximal descending aortic distensibility; β represents change in CMR measure units per 1 standard deviation [SD] increase in RVF in fully adjusted regression model 6; βSD represents the standard deviation change in the CMR measure per 1-SD increase in RVF in fully adjusted regression model 6; *p<0.05 **p<0.01

Figure 2: Standardised regression coefficient (βSD) for the 16 RVF-CMR associations in fully adjusted models

PDAoD: proximal descending aortic distensibility; LVEF: Left ventricle ejection fraction; LV GRS: Left ventricle global radial strain; EAT: Epicardial adipose tissue; LAVi: Left atrial max volume indexed to BSA; LV GLS: Left ventricle global longitudinal strain; Forest plot demonstrates standardised regression coefficients (βSD) with 95% confidence intervals for the association between each RVF and CMR measure in the fully adjusted model 6. βSD represents the standard deviation change in the CMR measure per 1-SD increase in RVF in the fully adjusted model 6. Dashed vertical line represents the null (βSD=0); *p<0.05 **p<0.01

Discussion

In this cohort of patients with type 2 diabetes, we demonstrate a range of novel and biologically coherent associations between measures of the retinal microvasculature and subclinical features of CV dysfunction. To our knowledge, this is the first study to identify several significant associations between AI-derived measures of the retinal microvasculature and comprehensive CMR phenotypes.

Venular tortuosity was significantly associated with LV T2 mean, LV global longitudinal strain and left atrial volume. These CMR measures are consistent with a pattern of early diffuse myocardial dysfunction from low grade myocardial inflammation (increased T2), to subclinical impairment of LV contractility (less negative values of longitudinal strain) and atrial remodelling (increased LA volume)[17,18,19]. The biological coherence of our findings is strengthened by the fact that this constellation of subclinical abnormalities is recognized to precede the development of overt heart failure syndromes[20]. Beyond venular tortuosity, we also noted that greater venular area was associated with increased proximal descending aortic distensibility and had a borderline association with better LV contractility (more positive values of radial strain). The directionality of these relationships aligns with previous findings that smaller retinal venular area is associated with an adverse cardiometabolic profile[21]. Overall, these associations support hypotheses that retinal venular abnormalities reflect microvascular pathology relevant to early CV disease[22]. While CV risk has traditionally focused on the arterial system, our findings suggest that the retinal venular bed also carries important information regarding CV dysfunction.

We also demonstrated associations between features of the retinal arteriolar bed and CMR measures. Greater arteriolar calibre uniformity was associated with lower LV T1 mean. This is also biologically coherent and suggests that deranged retinal arteriolar morphology may

reflect broader systemic fibrotic processes, including myocardial fibrosis. We also observed a

borderline association between greater arteriolar area and increases in proximal descending

aortic distensibility. This aligns with recent work demonstrating a positive correlation

between retinal arteriolar density and aortic distensibility[23], and reflects known shared

pathophysiological links between the microvasculature and large arteries[24]. Together, these

findings suggest that both the retinal arteriolar and venular beds can contribute to our

understanding of distinct elements of subclinical CV dysfunction.

We did not observe any significant relationships between LV functional or volumetric

parameters and RVF measures. This may support the hypothesis that changes in RVF are

primarily reflective of early microvascular dysfunction that precedes downstream structural

remodelling and functional disease.

In a comparable analysis of AI-derived retinal microvascular geometric features and CMR

measures of subclinical CV dysfunction, Alatrany *et al* reported a single association between

central retinal venular equivalents and LV mass/volume ratio[8]. In the present study, we

identified a broader set of associations, including a coherent venular tortuosity signature

encompassing LV T2, LV GLS, and LAVi. An explanation for this may be the distinct

methodological approaches taken to quantify geometric features of the retinal

microvasculature. Their study derived zone-based calibre equivalents from the largest retinal

vessels in the standard zone, whereas our study extracted a richer phenotype through

computing vessel-segment level measurements weighted by segment length across the full

microvascular tree. Additionally, our study incorporated a QUARTZ derived measure of

calibre uniformity, which was a significant predictor in our analysis. Our study also examined

a wider panel of CMR measures, including some that we found to be significant outcome

variables such as LV T1 and T2 mean, LAVi, and PDAoD. Finally, their end-to-end deep

learning models were applied to binary classification of the presence or absence of a set

pathological CMR threshold from retinal images. This is a fundamentally different analytic

approach to our explicit quantification of RVFs and regression against continuous CMR

measures, which may have resulted in a greater statistical power for us to detect significant

relationships.

A key strength of this study is that we demonstrated coefficient estimates that are biologically

coherent, directionally consistent, and stable across sensitivity analyses, with multivariable

regression models accounting for several potential confounders. Another strength was the use

of QUARTZ itself, which uses AI to extract a rich retinal vascular phenotype from across

whole images of varying quality and has been extensively validated for use in large clinical

and population-based studies[14]. The reproducibility and granularity of RVF estimates derived

from QUARTZ enabled more extensive and robust exploration of relationships with CMR

measures than those reported in other studies[8]. Additionally the type 2 diabetes cohort, while

disease-specific, provided sufficient variance in subclinical CMR measures to detect

associations while avoiding the potential confounding of established CV disease.

Limitations of this study include its small sample size, which meant we had limited power to

detect several potentially true associations. Sensitivity analysis with a ~10% reduction in

sample size indicated that our five statistically significant associations had stable effect sizes

and directionality, but significance was sometimes inconsistent across iterations. This

highlights the need for a larger study to increase precision of effect size estimates, evaluate

robustness of these findings, and determine the potential predictive utility of RVF measures.

While this diabetic cohort was appropriate for identifying subclinical cardiac dysfunction,

further study should include healthy controls and those with established CV disease. This will

test the generalisability of these findings and determine whether the observed associations are

diabetes-specific or exist across the spectrum of CV health. Additionally, it is known that

retinal vascular phenotype can vary between ethnic groups[25], and while we recruited a study

cohort who were ethnically diverse, our sample size precluded meaningful stratified analysis

by ethnicity. Finally, this was a cross-sectional study where the CMR could occur before or

after retinal image acquisition. Further prospective studies will enable ascertainment of the

temporality of the relationship between RVF and CMR measures and facilitate predictive

inferences.

The five significant associations we observed demonstrated a moderate magnitude of effect,

with a mean 0.21 SD change in CMR measure per 1-SD increase in RVF measure, consistent

with other epidemiological studies examining CMR against demographic and clinical

predictors[26]. The moderate absolute effect sizes likely reflect range restriction in a cohort

without overt CV disease. In a cohort with established CV disease, where CMR measures

would span a greater pathological range, larger and more clinically meaningful effect sizes

would be anticipated. However, this may itself inform the most appropriate use cases for

retinal vascular imaging. It is less likely this technique would be deployed to finalise the

binary presence or absence of CV disease. Rather, ours and others' findings point more

toward use in population health screening where the degree of subclinical CV dysfunction is

evaluated to inform prioritisation of further diagnostic investigations, such as CMR or

coronary angiography. Beyond atherosclerotic CV disease, our findings suggest potential

applications for conditions characterised by microvascular dysfunction such as heart failure

with preserved ejection fraction (HFpEF)[27] and ischaemia with non-obstructed coronary

arteries (INOCA)[28], as well as those at risk of aortic events or inherited cardiomyopathies.

These findings demonstrate that features of the retinal microvasculature are associated with

subclinical measures of CV dysfunction detected by CMR in patients with type 2 diabetes.

These are novel and biologically coherent associations that build on prior work through use

of a validated AI-enabled retinal image analysis tool. Our study establishes a foundation for

larger-scale replication and further investigation of these relationships with more directed

study design in other patient cohorts. This will enable testing the predictive potential of RVF

measures at different stages of CV disease processes and provide new mechanistic insights

into the shared pathophysiology of micro- and macrovascular disease. Collectively, our

findings strengthen the case for retinal imaging as a scalable and accessible method for

detecting and evaluating subclinical CV dysfunction.

Sources of funding

This study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The UKIDS trial is sponsored by Perspectum Ltd. The sponsor was involved in data collection, analysis, and interpretation. Use of the North East London Diabetic Eye Screening programme data was funded by Wellcome Collaborative award (224390/Z/21/Z). CW's time was funded by the National Institute for Health and Care Research.

Data availability statement

Anonymised individual patient data can be shared upon request or as required by law and/or regulation with qualified external researchers. Approval of such requests is at the discretion of the study sponsors and is dependent on the nature of the request, the availability of the data, and the intended use of the data.

Disclosures

MM, HTB, CD, and RP are employees at Perspectum Ltd., the company that developed CoverScan™ used in this study, and funded recruitment of participants to the UKIDS trial. HTB is also a shareholder at Perspectum Ltd. ERB receives grant funding from The British Heart Foundation for projects unrelated to this study.

Author contributions

CW, ARR, IY, MM, and CGO conceptualised the study. Study methodology was developed by CW, ARR, RAW, JF, SAB, CGO. Investigation was conducted by HED, CZ, IY, RDH, MM, HTB, CD, RP, JA, and RC. Formal analysis and interpretation were performed by CW and MM. The original manuscript was prepared by CW. All authors contributed to editing of the manuscript and approved the final version for submission. Supervision was provided by

423   ARR, MM, ERB, and CGO. CW had full access to all data in the study and takes

424   responsibility for their integrity and the accuracy of the data analysis.

427 **References**

---

[1] Rudnicka AR, Welikala RA, Barman SA, Foster PJ, Luben R, Hayat SA, et al. Artificial intelligence-enabled retinal vasculometry for prediction of circulatory mortality, myocardial infarction, and stroke. Br J Ophthalmol. 2022;106:1722–1729.

[2] Chandra A, Seidelmann SB, Claggett BL, Klein BEK, Klein R, Shah AM, Solomon SD. The association of retinal vessel calibres with heart failure and long-term alterations in cardiac structure and function: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Heart Fail. 2019;21:1207–1215.

[3] McGeechan K, Liew G, Macaskill P, Irwig L, Klein R, Sharrett AR, et al. Risk prediction of coronary heart disease based on retinal vascular calibre (from the Atherosclerosis Risk In Communities [ARIC] Study). Am J Cardiol. 2008;102:58–63.

[4] McGeechan K, Liew G, Macaskill P, Irwig L, Klein R, Klein BEK, et al. Prediction of incident stroke events based on retinal vessel calibre: a systematic review and individual-participant meta-analysis. Am J Epidemiol. 2009;170:1323–1332.

[5] Huang L, Aris IM, Teo LLY, Wong TY, Chen WQ, Koh AS, Li LJ. Exploring associations between cardiac structure and retinal vascular geometry. J Am Heart Assoc. 2020;9:e014654.

[6] Tapp RJ, Owen CG, Barman SA, Welikala RA, Foster PJ, Whincup PH, et al. Associations of retinal microvascular diameters and tortuosity with blood pressure and arterial stiffness: United Kingdom Biobank. Hypertension. 2019;74:1383–1390.

[7] Cheung N, Sharrett AR, Klein R, Criqui MH, Islam FMA, Macura KJ, et al. Aortic distensibility and retinal arteriolar narrowing: the multi-ethnic study of atherosclerosis. Hypertension. 2007;50:617–622.

[8] Alatrany AS, Lakhani K, Cowley AC, Yeo JL, Dattani A, Ayton SL, et al. The retina as a window into detecting subclinical cardiovascular disease in type 2 diabetes. Sci Rep. 2025 Jul 31;15(1):27968.

[9] Liew G, Wang JJ, Mitchell P, Wong TY. Retinal vascular imaging: a new tool in microvascular disease research. Circ Cardiovasc Imaging. 2008;1:156–161.

[10] Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009;53:S35–S42.

[11] Cheung CY, Ikram MK, Klein R, Wong TY. The clinical implications of recent studies on the structure and function of the retinal microvasculature in diabetes. Diabetologia. 2015;58:871–885.

[12] Owen CG, Rudnicka AR, Welikala RA, Fraz MM, Barman SA, Luben R, et al. Retinal vasculometry associations with cardiometabolic risk factors in the European Prospective Investigation of Cancer-Norfolk Study. Ophthalmology. 2019;126:96–106.

[13] Dennis A, Cuthbertson DJ, Wootton D, Crooks M, Gabbay M, Eichert N, et al. Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study. J R Soc Med. 2023;116:97–112.

[14] Welikala RA, Fajtl J, Johnson G, Rahman F, Podoleanu R, Remagnino P, et al. Artificial intelligence-enabled retinal vasculometry at scale utilizing the UK Biobank, CLSA, and NEL DESP datasets. In: 2024 IEEE EMBS International Conference on Biomedical and Health Informatics (BHI). IEEE; 2024:1–8. [Abstract]

[15] Quigley HA, Brown AE, Morrison JD, Drance SM. The size and shape of the optic disc in normal human eyes. Arch Ophthalmol. 1990;108:51–57.

[16] van der Meer RW, Diamant M, Westenberg JJ, Doornbos J, Bax JJ, de Roos A, et al. Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson. 2007;9:645–651.

[17] Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72:3158–3176.

[18] Hirose K, Nakanishi K, Daimon M, Sawada N, Konoma S, Kobayashi S, et al. Association of PREVENT risk model with body fat distribution and subclinical left ventricular dysfunction. Am J Prev Cardiol. 2025;25:101368.

[19] Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, et al. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol. 2006;47:2357–2363.

[20] Moura B, Aimo A, Al-Mohammad A, Flammer A, Barberis V, Bayes-Genis A, et al. Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23:1577–1596.

[21] O'Neil A, Welikala RA, Barman SA, Owen CG, Rudnicka AR, Rakesh M, et al. Factors associated with retinal vessel traits in the Canadian Longitudinal Study on Aging. Invest Ophthalmol Vis Sci. 2025;66:13.

[22] Ikram MK, Cheung CY, Lorenzi M, Klein R, Jones TL, Wong TY. Retinal vascular calibre as a biomarker for diabetes microvascular complications. Diabetes Care. 2013;36:750–759.

[23] Ortín Vela S, Bergmann S. Cross-organ analysis reveals associations between vascular properties of the retina, the carotid and aortic arteries, and the brain. Commun Med. 2026;6:102.

[24] Mitchell GF, Vita JA, Larson MG, Parise H, Keyes MJ, Warner E, et al. Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. Circulation. 2005;112:3722–3728.

[25] Sun C, Wang JJ, Mackey DA, Wong TY. Retinal vascular calibre: systemic, environmental, and genetic associations. Surv Ophthalmol. 2009;54:74–95.

[26] Raisi-Estabragh Z, Jaggi A, Gkontra P, McCracken C, Aung N, Munroe PB, et al. Cardiac magnetic resonance radiomics reveal differential impact of sex, age, and vascular risk factors on cardiac structure and myocardial tissue. Front Cardiovasc Med. 2021;8:763361.

[27] Bilak JM, Alam U, Miller CA, McCann GP, Arnold JR, Kanagala P. Microvascular dysfunction in heart failure with preserved ejection fraction: pathophysiology, assessment, prevalence and prognosis. Card Fail Rev. 2022;8:e24.

[28] Ashokprabhu ND, Quesada O, Alvarez YR, Henry TD. INOCA/ANOCA: mechanisms and novel treatments. Am Heart J Plus. 2023;30:100302.